750 related articles for article (PubMed ID: 16982227)
21. Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism.
Jick SS; Hagberg KW; Hernandez RK; Kaye JA
Contraception; 2010 Jan; 81(1):16-21. PubMed ID: 20004268
[TBL] [Abstract][Full Text] [Related]
22. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
Farmer RD; Lawrenson RA
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S78-86. PubMed ID: 9753314
[TBL] [Abstract][Full Text] [Related]
23. The use of a large-scale surveillance system in Planned Parenthood Federation of America clinics to monitor cardiovascular events in users of combination oral contraceptives.
Burnhill MS
Int J Fertil Womens Med; 1999; 44(1):19-30. PubMed ID: 10206196
[TBL] [Abstract][Full Text] [Related]
24. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
Meurer LN; Slawson JG
J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554
[No Abstract] [Full Text] [Related]
25. Effect of combined low-dose oral contraceptives on blood viscosity and haematocrit.
Ishak R; Loh Chooi Khim
Malays J Reprod Health; 1991 Jun; 9(1):5-8. PubMed ID: 12317443
[TBL] [Abstract][Full Text] [Related]
26. Ethinylestradiol + etonogestrel contraceptive vaginal ring: new drug. Possibly useful in some situations.
Prescrire Int; 2006 Apr; 15(82):50-3. PubMed ID: 16604729
[TBL] [Abstract][Full Text] [Related]
27. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
[TBL] [Abstract][Full Text] [Related]
28. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women.
Lewis MA; Heinemann LA; MacRae KD; Bruppacher R; Spitzer WO
Contraception; 1996 Jul; 54(1):5-13. PubMed ID: 8804801
[TBL] [Abstract][Full Text] [Related]
29. Newer non-oral hormonal contraception.
Bateson D; McNamee K; Briggs P
BMJ; 2013 Feb; 346():f341. PubMed ID: 23412438
[No Abstract] [Full Text] [Related]
30. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare".
Heinemann LA; Dinger JC; Assmann A; Minh TD
Contraception; 2010 May; 81(5):401-7. PubMed ID: 20399946
[TBL] [Abstract][Full Text] [Related]
31. The combined vaginal contraceptive ring, nuvaring, and cerebral venous sinus thrombosis: a case report and review of the literature.
Kolacki C; Rocco V
J Emerg Med; 2012 Apr; 42(4):413-6. PubMed ID: 21945504
[TBL] [Abstract][Full Text] [Related]
32. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?
Odlind V; Milsom I; Persson I; Victor A
Acta Obstet Gynecol Scand; 2002 Jun; 81(6):482-90. PubMed ID: 12047300
[TBL] [Abstract][Full Text] [Related]
33. Use of low-dose oral contraceptives and stroke in young women.
Schwartz SM; Siscovick DS; Longstreth WT; Psaty BM; Beverly RK; Raghunathan TE; Lin D; Koepsell TD
Ann Intern Med; 1997 Oct; 127(8 Pt 1):596-603. PubMed ID: 9341057
[TBL] [Abstract][Full Text] [Related]
34. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10.
Lidegaard O; Nielsen LH; Skovlund CW; Løkkegaard E
BMJ; 2012 May; 344():e2990. PubMed ID: 22577198
[TBL] [Abstract][Full Text] [Related]
35. Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database.
Murphy PA; Brixner D
Contraception; 2008 Apr; 77(4):257-63. PubMed ID: 18342648
[TBL] [Abstract][Full Text] [Related]
36. Oral contraceptive pills and the risk of venous thromboembolism.
Prog Hum Reprod Res; 1996; (39):2-3. PubMed ID: 12292198
[TBL] [Abstract][Full Text] [Related]
37. Hormonal contraceptives as a risk factor for cerebral venous and sinus thrombosis.
Saadatnia M; Tajmirriahi M
Acta Neurol Scand; 2007 May; 115(5):295-300. PubMed ID: 17489938
[TBL] [Abstract][Full Text] [Related]
38. Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate.
Chez RA
Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1296-300. PubMed ID: 2524163
[TBL] [Abstract][Full Text] [Related]
39. The new era in oral contraception: pills containing gestodene, norgestimate, and desogestrel.
London RS
Obstet Gynecol Surv; 1992 Nov; 47(11):777-82. PubMed ID: 1436906
[TBL] [Abstract][Full Text] [Related]
40. Ethinylestradiol + norelgestromin: new preparation. Transdermal contraception: no tangible progress.
Prescrire Int; 2004 Aug; 13(72):123-6. PubMed ID: 15532134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
